Human intestinal innate lymphoid cells (ILCs): signatures and polarization signals
Human intestinal innate lymphoid cells (ILCs): signatures and polarization signals
批准号:
289483678
负责人:
Professorin Dr. Chiara Romagnani, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2016
资助国家:
德国
项目状态:
已结题
起止时间:
2015-12-31 至 2018-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The immune system responds to pathogen infection by employing distinct effector modules, namely type 1 (Interferon-gamma and Tumor necrosis factor), type 2 (Interleukin-, IL-4, IL-5 and IL-13) and type 3 or 17 (IL-17, IL-22), which are tailored to eliminate the different infectious agents and differentially contribute to drive chronic inflammation, especially inflammatory bowel diseases (IBD). This heterogeneity of effector programs has been extensively characterized among CD4+ T helper (Th) cells which can be accordingly dissected in three main subsets, namely Th1, Th2 and Th17 cells. It is now evident that an emerging family of innate lymphoid cells (ILCs, comprising of Natural Killer cells, ILC1, ILC2 and ILC3), exhibit an analogous heterogeneity of effector programs as described for T cells. Thus, it was shown that different ILC subsets, preferentially residing in the intestine, can play an important role in inducing colitis. On the other hand, ILCs can also contribute to mucosal tissue homeostasis and intestinal epithelial cell regeneration after damage. The signals responsible for the differentiation toward different ILC subset fate and for the imprinting of the correspondent effector programs remain largely unclear, especially in humans.This project is devoted to study the signals required for the differentiation and imprinting of inflammatory and regulatory programs employed by distinct human ILC subsets and to establish protocols for their generation and expansion. We postulate that the intestine might represent a preferential differentiation site for ILCs, especially ILC3, and that gut microenvironment might provide important signals to skew ILC fate. The comparative analysis of human intestinal ILCs and of their precursors with those generated in vitro upon exposure to different stimuli will enable us to get insights on how, where and when distinct effector programs are acquired by ILCs. Because of their crucial role as regulators of inflammatory processes and tissue homeostasis, this project will enable not only to extend our understanding of ILC biology, but also to possibly identify novel therapeutic strategies for the treatment of inflammatory diseases.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/imr.12712
发表时间:
2018-10
期刊:
Immunological Reviews
影响因子:
8.7
作者:
[Christina Stehle;Daniela C Hernández;C. Romagnani]
通讯作者:
Christina Stehle;Daniela C Hernández;C. Romagnani
Innate mechanisms of chronic inflammation
-
批准号:288867951
-
项目类别:Heisenberg Professorships
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professorin Dr. Chiara Romagnani, Ph.D.
-
依托单位:
Role of Innate lymphoid cells (ILC) and aryl hydrocarbon receptor (AhR) during pulmonary bacterial infections
-
批准号:320429054
-
项目类别:Priority Programmes
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professorin Dr. Chiara Romagnani, Ph.D.
-
依托单位:
Mechanisms of Natural Killer cell expansion and neoplastic transformation
-
批准号:497784080
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professorin Dr. Chiara Romagnani, Ph.D.
-
依托单位:
国内基金
海外基金
登录
查看更多内容
西方饮食通过“肠道菌群-Rspo1”轴促进肥胖与肠道吸收的机制研究
-
批准号:82370845
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:洪洁
-
依托单位:
新生儿坏死性小肠结肠炎中去泛素化酶USP15调控ILC3分化损伤肠道粘膜屏障的致病机制研究
-
批准号:82371711
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:吕志宝
-
依托单位:
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
-
批准号:82370902
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:田景琰
-
依托单位:
短链脂肪酸上调小肠上皮紧密连接屏障功能的机制
-
批准号:31040041
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:王鹏远
-
依托单位: